- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objective: • To assess the efficacy, in term of PSA response rate, of multiple doses of CP 751,871 in combination with docetaxel and prednisone in patients with HRPC.
Critère d'inclusion
- Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)